COMPARATIVE ANALYSIS OF PULMONARY HYPERTENSION IN THE 105 CML PATIENTS TREATED WITH IMATINIB, NILOTINIB AND DASATINIB

被引：0
作者：
Minami, M. [1 ]
Miyamoto, T. [1 ]
Akashi, K. [1 ]
机构：
[1] Kyushu Univ, Dept Med & Biosyst Sci, Fukuoka, Japan
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1816
引用
收藏
页码：728 / 728
页数：1
相关论文
共 50 条
  • [31] A dose-response study of nilotinib and imatinib in experimental pulmonary hypertension
    Chaumais, Marie-Camille
    Perros, Frederic
    Molimard, Mathieu
    Bouchet, Stephane
    Dorfmuller, Peter
    Guignabert, Christophe
    Cohen-Kaminsky, Sylvia
    Humbert, Marc
    Montani, David
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [32] Incidence of grade 3/4 adverse events in imatinib resistant/intolerant chronic phase CML (CP-CML): A comparison of nilotinib and dasatinib
    Carpiuc, K. T.
    Stephens, J. M.
    Liou, S. Y.
    Botteman, M. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] NILOTINIB IS ACTIVE IN IMATINIB RESISTANT AND INTOLERANT CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
    Koren-Michowitz, M. K. M.
    Le Coutre, P.
    Duyster, J.
    Scheid, C.
    Rowe, J. M.
    Goldschmidt, N.
    Ribakovsky, E.
    Nagler, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 222 - 223
  • [34] Grade 3/4 adverse events in imatinib resistant/intolerant chronic phase CML (CML-CP) patients treated with nilotiniband dasatinib
    Stephens, J.
    Carpiuc, K. T.
    Snedecor, S. J.
    Botteman, M. F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 205 - 206
  • [35] Recurrent Pleural Effusions and Evidence of Pulmonary Arterial Hypertension on Bosutinib in a CML Patient Previously Treated With Dasatinib Therapy
    Beale, P.
    Hourigan, E. K.
    Collins, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [36] A cost-utility analysis of nilotinib for CML patients who have become resistant to imatinib.
    Pilgrim, H.
    Jewitt, K.
    Ward, S.
    BLOOD, 2007, 110 (11) : 376B - 376B
  • [37] Efficacy and safety of bosutinib in patients treated with prior imatinib and/ or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study
    Smith, B. Douglas
    Bruemmendorf, Tim H.
    Roboz, Gail J.
    Gambacorti-Passerini, Carlo
    Charbonnier, Aude
    Viqueira, Andrea
    Leip, Eric
    Purcell, Simon
    Goldman, Erinn Hoag
    Giles, Francis
    Ernst, Thomas
    Hochhaus, Andreas
    Rosti, Gianantonio
    LEUKEMIA RESEARCH, 2024, 139
  • [38] Preclinical analysis of immunosuppressive and cytotoxic effects of imatinib, nilotinib and dasatinib in combination with cyclosporine A or rapamycin
    Ayuk, F.
    Friesicke, M.
    Sonntag, T.
    Zander, A. R.
    Kroeger, N.
    Fehse, B.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S183 - S183
  • [39] BUDGET IMPACT ANALYSIS OF DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) IN BRAZIL
    Asano, E.
    Nita, M.
    Moellmann-Coelho, A.
    Rached, R.
    Donato, B.
    Rahal, E.
    VALUE IN HEALTH, 2009, 12 (07) : A262 - A262
  • [40] REAL-LIFE COMPARISON OF DASATINIB AND NILOTINIB AS SECOND-LINE THERAPY AFTER IMATINIB FAILURE FOR CHRONIC PHASE CML
    Tiribelli, M.
    Bonifacio, M.
    Binotto, G.
    Iurlo, A.
    Cibien, F.
    Maino, E.
    Guella, A.
    Festini, G.
    Minotto, C.
    De Biasi, E.
    De Marchi, F.
    Scaffidi, L.
    Frison, L.
    Bucelli, C.
    Medeot, M.
    Calistri, E.
    Sancetta, R.
    Stulle, M.
    Krampera, M.
    Gherlinzoni, F.
    Semenzato, G.
    Ambrosetti, A.
    Fanin, R.
    HAEMATOLOGICA, 2016, 101 : 237 - 238
12345